The mechanism by which DLBCL patients develop resistance to R-CHOP is currently unclear and understanding the molecular basis of this treatment failure is crucial for improving clinical outcome of DLBCL patients. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.